PTAB Releases Stats on Pilot Programs Aimed at Limiting Appeal Inventory
February 02, 2016
Authored and Edited by Amanda K. Murphy, Ph.D.; Stephanie M. Sanders
During its PTAB Boardside Chat on February 2, 2016, Lead Judge Jeffrey Robertson provided statistics on the two pilot programs intended to reduce the overall number of appeals pending before the Board: the Expedited Patent Appeal Pilot (EPAP) program and the Streamlined Expedited Patent Appeal Pilot (S-EPAP) program for Small Entities, both of which have been discussed in previous blog posts.
The following chart provides the statistics cited during the Chat, which are current through January 6, 2016.
| Expedited Patent Appeal Pilot (EPAP) Program | Streamlined Expedited Patent Appeal Pilot (S-EPAP) Program for Small Entities | |
| Number of petitions filed | 22 | 15 |
| Number of petitions granted | 20 | 10 |
| Number of petitions denied | 2 | 5 |
| Time to decide petition | 2 says | 11 days |
Both the EPAP and S-EPAP for Small Entity programs will be available for about a year (from June 19, 2015 to June 20, 2016 for EPAP, and from September 18, 2015 to September 16, 2016 for S-EPAP for Small Entities) or until two thousand (2,000) appeals have been accorded special status under each program, whichever occurs earlier. Based on these initial numbers, it appears that the pilot programs will expire well before that two thousand mark is met.
Contacts
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
